Guobang Pharma Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Cash & Equivalents	1,312	1,909	2,094	1,974	893.01	1,235
Trading Asset Securities	896.34	617.66	465.99	824.56	1,258	0.03
Cash & Short-Term Investments	2,208	2,527	2,560	2,799	2,151	1,235
Cash Growth	2.21%	-1.29%	-8.52%	30.09%	74.24%	-2.38%
Accounts Receivable	1,424	1,332	964.92	775.34	571.5	544.51
Other Receivables	16.59	17.97	17.22	21.07	45.03	30.83
Receivables	1,441	1,350	982.14	796.41	616.53	575.34
Inventory	1,623	1,363	1,369	1,409	1,309	989.55
Prepaid Expenses	-	-	-	-	0.7	-
Other Current Assets	479.55	634.05	532.31	125.15	489.48	71.64
Total Current Assets	5,752	5,874	5,443	5,129	4,567	2,871
Property, Plant & Equipment	4,272	4,344	4,330	3,284	2,622	2,152
Long-Term Investments	115.81	112.57	121.13	101.37	17.11	18.67
Goodwill	0.03	0.03	0.03	0.03	0.03	0.03
Other Intangible Assets	344.59	350.83	358.85	370.5	272.26	266.71
Long-Term Deferred Tax Assets	10.8	8.96	7.78	6.59	19.02	12.01
Long-Term Deferred Charges	7.1	7.45	8.02	9.26	2.6	3.37
Other Long-Term Assets	76.59	82.64	92.64	142.61	12.79	184.52
Total Assets	10,579	10,780	10,362	9,043	7,513	5,509
Accounts Payable	1,118	1,704	1,715	974.35	789.71	1,096
Accrued Expenses	77.52	125.97	97.06	107.06	100.47	86.68
Short-Term Debt	441.42	181.23	488.79	664.28	168.88	518.12
Current Portion of Long-Term Debt	37.98	452.17	28.88	-	-	150.25
Current Income Taxes Payable	49.93	22.47	18.44	4.26	30.24	23.57
Current Unearned Revenue	32.87	39.93	55.85	52.79	30.68	42.71
Other Current Liabilities	38.17	32.34	45.99	59.64	33.53	55.39
Total Current Liabilities	1,796	2,558	2,450	1,862	1,154	1,972
Long-Term Debt	478.71	146.72	451.7	-	-	251
Long-Term Unearned Revenue	23.44	16.67	11.8	14.27	9.71	8.27
Long-Term Deferred Tax Liabilities	5.87	7.2	11.32	11.93	4.16	2.69
Total Liabilities	2,304	2,728	2,924	1,889	1,167	2,234
Common Stock	558.82	558.82	558.82	558.82	558.82	475
Additional Paid-In Capital	3,608	3,609	3,607	3,607	3,607	1,047
Retained Earnings	4,216	3,881	3,266	2,989	2,180	1,753
Treasury Stock	-111.13	-1.48	-	-	-	-
Total Common Equity	8,272	8,047	7,432	7,155	6,346	3,275
Minority Interest	3.63	4.72	5.15	-0.65	-0.39	-0.58
Shareholders' Equity	8,275	8,052	7,437	7,155	6,346	3,274
Total Liabilities & Equity	10,579	10,780	10,362	9,043	7,513	5,509
Total Debt	958.11	780.12	969.37	664.28	168.88	919.37
Net Cash (Debt)	1,250	1,747	1,591	2,134	1,982	315.27
Net Cash Growth	-0.10%	9.81%	-25.46%	7.66%	528.79%	12.17%
Net Cash Per Share	2.25	3.13	2.86	3.82	3.87	0.67
Filing Date Shares Outstanding	550.61	558.37	555.51	558.82	558.82	475
Total Common Shares Outstanding	550.61	558.74	558.82	558.82	558.82	475
Working Capital	3,956	3,317	2,994	3,267	3,414	898.7
Book Value Per Share	15.02	14.40	13.30	12.80	11.36	6.89
Tangible Book Value	7,927	7,696	7,073	6,785	6,074	3,008
Tangible Book Value Per Share	14.40	13.77	12.66	12.14	10.87	6.33
Buildings	-	1,812	1,706	1,025	810.75	717
Machinery	-	3,980	3,372	2,487	1,933	1,646
Construction In Progress	-	255.26	636.65	874.85	827.46	571.04

Source: S&P Global Market Intelligence. Standard template. Financial Sources.